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Introduction
One of the most important manifestations of mucopoly-
saccharidosis (MPS) type I, II and VI is a progressive
disease of the osteoarticular system. The evaluation of the
disease advancement is difficult due to the complexity of
symptoms. The characteristic features are progressive limi-
tation of joint mobility and joint pain. These symptoms
affect the quality of patient life. A uniform scale has not
been developed for these patients.
Objectives
The aim of this study was to use the experience in the
evaluation of disorders in rheumatic diseases (Juvenile
Idiopathic Arthritis, JIA) in patients with MPS.
Methods
6 patients with MPS VI were evaluated: 2 with advanced
disease, 2 with moderate and 2 with slow progressing
disease. The following parameters were selected for assess-
ment: Physician global assessment of disease activity
(PGA), Patient/parent global assessment of well-being
(PGE), Functional ability (CHAQ), Number of joints with
limited movement (LJC) and VAS pain – visual analogue
scale for pain.
Results
The evaluation results are shown in Table 1.
Conclusion
The parameters used in JIA may be applied for assessment
of the MPS severity. With their implementation, the pro-
gression of the disease and the effect of the treatment can
be assessed and compared.
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1 35 1.0 0 0.375 2 1.0 4.375 mild
2 21 2.0 0 1.125 2 0 5.125 ↓
3 9 2.0 0 0 7 2.0 9 ↓
4 16 2.0 0 0.125 8 0 10.125 ↓
5 5 3.0 1,0 0 21 1.0 26 ↓
6 11 3.0 0 0.125 37 3.5 43.625 advanced
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